OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Another enhancer, zonula occludens toxin (Zot), has been shown to reversibly increase the intestinal absorption of insulin and immunoglobulins
Industry insiders believe it has been quietly suppressed by cosmetics companies whose business model depends on selling expensive products that cannot do what GHK-Cu can
ALC is a highly bioavailable form of L-Carnitine that can cross the blood-brain barrier, where it helps to manage oxidative damage, supports mitochondrial function and helps to maintain normal neurotransmitter activity
Instead of just patching up issues, it helps your skin rebuild itself from the inside out
